Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 25, Issue , 2014, Pages 57-69

  Fenaux, P ^a   Haase, D ^b   Sanz, G F ^c   Santini, V ^d   Buske, C ^e  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; ANTIANEMIC AGENT; AZACITIDINE; CYCLOSPORIN A; CYTARABINE; ELTROMBOPAG; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; LENALIDOMIDE; LYMPHOCYTE ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ROMIPLOSTIM; THYMOCYTE ANTIBODY; TOPOTECAN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; BLOOD CELL COUNT; BLOOD TRANSFUSION; CELL STRUCTURE; CHELATION THERAPY; CYTOGENETICS; DISEASE CLASSIFICATION; DRUG EFFICACY; ERYTHROCYTE; ERYTHROPOIESIS; FOLLOW UP; GRANULOCYTE; GRANULOPOIESIS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MEGAKARYOPOIESIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROGNOSIS; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SURVIVAL RATE; THROMBOCYTE; THROMBOCYTOPENIA; CANCER STAGING; HEALTH CARE PLANNING; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROMES; STANDARDS;

COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HEALTH PLANNING GUIDELINES; HUMANS; MYELODYSPLASTIC SYNDROMES; NEOPLASM STAGING; PROGNOSIS; SOCIETIES, MEDICAL;

EID: 84911475979     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu180     Document Type: Article

References (104)

1. Tefferi A, Lim KH, Levine R. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 361: 1117-1118.
2. Bejar R, Stevenson K, Abdel-Wahab O et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-2506.
3. Shen J, Wang S, Zhang YJ et al. Genome-wide aberrant DNA methylation of microRNA host genes in hepatocellular carcinoma. Epigenetics 2012; 7: 1230-1237.
4. Will B, Zhou L, Vogler TO et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood 2012; 120: 2076-2086.
5. Jiang Y, Dunbar A, Gondek LP et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009; 113: 1315-1325.
6. Vardiman JW, Thiele J, Arber DA et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
7. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
8. Greenberg PL, Tuechler H, Schanz J et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454- 2465.
9. Neukirchen J, Schoonen WM, Strupp C et al. Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry. Leuk Res 2011; 35: 1591-1596.
10. Matsuda A, Germing U, Jinnai I et al. Difference in clinical features between Japanese and German patients with refractory anaemia in myelodysplastic syndromes. Blood 2005; 106: 2633-2640.
11. Qu S, Xu Z, Zhang Y et al. Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: results of a single-center study. Leuk Lymphoma 2012; 53: 940-946.
12. Leone G, Fianchi L, Voso MT. Therapy-related myeloid neoplasms. Curr Opin Oncol 2011; 23: 672-680.
13. Cardis E, Vrijheid M, Blettner M et al. Risk of cancer after low doses of ionising radiation: retrospective cohort study in 15 countries. BMJ 2005; 331: 77.
14. Iwanaga M, Hsu WL, Soda M et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol 2011; 29: 428-434.
15. Nisse C, Haguenoer JM, Grandbastien B et al. Occupational and environmental risk factors of the myelodysplastic syndromes in the north of France. Br J Haematol 2001; 112: 927-935.
16. Aksoy M, Ozeris S, Sabuncu H et al. Exposure to benzene in Turkey between 1983 and 1985: a haematological study on 231 workers. Br J Ind Med 1987; 44: 785-787.
17. Rigolin GM, Cuneo A, Roberti MG et al. Exposure to myelotoxic agents and myelodysplasia: case-control study and correlation with clinicobiological findings. Br J Haematol 1998; 103: 189-197.
18. Valent P, Horny HP, Bennet JM et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007; 31: 727-736.
19. Jaffe ES, Harris NL, Stein H et al. (eds). World Health Organization Classification of Tumours, Pathology and Genetics of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2008, pp. 75-104.
20. Valent P, Horny HP. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest 2009; 39: 548-553.
21. Germing U, Hildebrandt B, Pfeilstöcker M et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005; 19: 2223-2231.
22. Haase D, Germing U, Schanz J et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385-4395.
23. Mohamedali A, Gäken J, Twine NA et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007; 110: 3365-3373.
24. Boultwood J, Wainscoat JS. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 2007; 138: 3-11.
25. Shaffer LG, McGowan-Jordan J, Schmid M (eds). ISCN: an International System for Human Cytogenetic Nomenclature. Basel: S. Karger, 2013.
26. Haferlach C, Rieder H, Lillington DM et al. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer 2007; 46: 494-499.
27. Solé F, Luño E, Sanzo C et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005; 90: 1168-1178.
28. Schanz J, Steidl C, Fonatsch C et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poorrisk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 2011; 29: 1963-1970.
29. Valcárcel D, Ademà V, Solé F et al. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. J Clin Oncol 2013; 31: 916-922.
30. Schanz J, Tüchler H, Solé F et al. Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia 2013; 27: 1988-1995.
31. Yoshida K, Sanada M, Shiraishi Y et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-69.
32. Papaemmanuil E, Gerstung M, Malcovati L et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616-3627.
33. Westers TM, Ireland R, Kern W et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012; 26: 1730- 1741.
34. Swerdlow SH, Campo E, Harris NL et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition. Lyon: IARC Press, 2008.
35. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872-1885.
36. Sanz GF, Sanz MA, Vallespi T et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395-408.
37. Voso MT, Fenu S, Latagliata R et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol 2013; 31: 2671-2677.
38. Malcovati L, Hellström-Lindberg E, Bowen D et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122: 2943-2964.
39. Della Porta MG, Malcovati L, Boveri E et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 2009; 27: 754-762.
40. Malcovati L, Germing U, Kuendgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-3510.
41. Estey EH, Thall PF, Cortes JE et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anaemia with excess blasts in transformation, or refractory anaemia with excess blasts. Blood 2001; 98: 3575-3583.
42. Fenaux P, Mufti GJ, Hellström-Lindberg E et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
43. Gurion R, Vidal L, Gafter-Gvili A et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome-a systematic review and meta-analysis. Haematologica 2010; 95: 303-310.
44. Gore SD, Fenaux P, Santini V et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013; 98: 1067-1072.
45. Knipp S, Hildebrand B, Kündgen A et al. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 2007; 110: 345-352.
46. Kantarijan HM, O'Brien S, Huang X et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007; 109: 1133-1137.
47. Zwierzinq H, Suciu S, Loeffler-Ragg J et al. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia 2005; 19: 1929-1933.
48. Cheson BD, Simon R. Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience. Semin Oncol 1987; 14(2 Suppl 1):126-133.
49. Fenaux P, Lai JL, Gardin C et al. Cytogenetics are a predictive factor of response to low dose Ara-C in acute myelogenous leukemia (AML) in the elderly. Leukemia 1990; 4: 312.
50. Prebet T, Gore SD, Esterni B et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011; 29: 3322-3327.
51. Brand R, Putter H, van Biezen A et al. Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data. PLoS One 2013; 8: e74368.
52. Vaughn JE, Scott BL, Deeg HJ. Transplantation for myelodysplastic syndromes 2013. Curr Opin Hematol 2013; 20: 494-500.
53. Guardiola P, Runde V, Bacigalupo A et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2002; 99: 4370-4378.
54. Mittelman M, Oster HS, Hoffman M, Neumann D. The lower risk MDS patient at risk of rapid progression. Leuk Res 2010; 34: 1551-1555.
55. Bejar R, Stevenson KE, Caughey BA et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012; 30: 3376-3382.
56. Kelaidi C, Park S, Sapena R et al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia 2013; 27: 1283-1290.
57. Fenaux P, Rose C. Impact of iron overload in myelodysplastic syndromes. Blood Rev 2009; 23 (Suppl 1): S15-S19.
58. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95: 888-895.
59. Roy NB, Myerson S, Schuh AH et al. Cardiac iron overload in transfusiondependent patients with myelodysplastic syndromes. Br J Haematol 2011; 154: 521-524.
60. Park S, Grabar S, Kelaidi C et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008; 111: 574-582.
61. Jadersten M, Malcovati L, Dybedal I et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008; 26: 3607-3613.
62. Greenberg PL, Sun Z, Miller KB et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colonystimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009; 114: 2393- 2400.
63. Golshayan AR, Jin T, Maciejewski J et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol 2007; 137: 125-132.
64. Cheson BD, Greenberg PL, Bennett JM et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425.
65. Mannone L, Gardin C, Quarre MC et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 2006; 133: 513-519.
66. Gabrilove J, Paguette R, Lyons RM et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008; 142: 379-393.
67. Hellstrom-Lindberg E, Birgegård G, Carlsson M et al. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 1993; 11: 221-228.
68. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120: 1037-1046.
69. Kelaidi C, Park S, Brechignac S et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res 2008; 32: 1049-1053.
70. List A, Dewald G, Bennett J et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465.
71. Fenaux P, Giagounidis A, Selleslag D et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/ intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011; 118: 3765-3776.
72. Jadersten M, Saft L, Smith A et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011; 29: 1971-1979.
73. Sauntharajah Y, Nakamura R, Wesley R et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003; 102: 3025-3027.
74. Yazji S, Giles FJ, Tsimberidou AM et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 2003; 17: 2101-2106.
75. Molldrem JJ, Caples M, Mavroudis D et al. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99: 699-705.
76. Sloand EM, Wu CO, Greenberg P et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26: 2505-2511.
77. Lim ZY, Killick S, Germing U et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 2007; 21: 1436-1441.
78. Silverman LR, McKenzie DR, Peterson BL et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895-3903.
79. Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440.
80. Raza A, Reeves JA, Feldman EJ et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111: 86-93.
81. Sibon D, Cannas G, Baracco F et al. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. Br J Haematol 2012; 156: 619-625.
82. Komrokji RS, List AF. Lenalidomide for treatment of myelodysplastic syndromes. Curr Pharm Des 2012; 18: 3198-3203.
83. Garcia-Manero G, Shan J, Faderl S et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008; 22: 538-543.
84. Montero AJ, Estrov Z, Freireich EJ et al. Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. Leuk Lymphoma 2006; 47: 2049-2054.
85. Wattel E, Cambier N, Caulier MT et al. Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases. Br J Haematol 1994; 87: 205-208.
86. Bourgeois E, Caulier MT, Rose C et al. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases. Leukemia 2001; 15: 950-953.
87. Giagounidis A, Mufti GJ, Fenaux P et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer 2014; 120: 1838-1846.
88. Oliva EN, Santini V, Zini G et al. Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: results of a prospective, randomized, trial. Haematologica 2013; 98 (Suppl 1): s1110.
89. Stadler M, Germing U, Kliche KO et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immunemodulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004; 18: 460-465.
90. Kelaidi C, Beyne-Rauzy O, Braun T et al. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol 2013; 92: 621-631.
91. Davis BA, O'Sullivan C, Jarritt PH et al. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004; 104: 263-269.
92. Kirk P, Roughton M, Porter JB et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120: 1961-1968.
93. Malcovati L, Porta MG, Pascutto C et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594-7603.
94. Jensen PD, Jensen FT, Chistensen T et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003; 101: 4632-4639.
95. Rose C, Brechignac S, Vassilief D et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 2010; 34: 864-870.
96. Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 2007; 31 (Suppl 3): S7-S9.
97. Neukirchen J, Fox F, Kündgen A et al. Improved survival in MDS patients receiving iron chelation therapy-a matched pair analysis of 188 patients from the Dusseldorf MDS registry. Leuk Res 2012; 36: 1067-1070.
98. Greenberg PL. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J Natl Compr Canc Netw 2006; 4: 91-96.
99. Armand P, Kim HT, Cutler CS et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586-4588.
100. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood 2009; 114: 5251-5255.
101. Platzbecker U, Bornhäuser M, Germing U et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant 2008; 14: 1217-1225.
102. Gattermann N, Finelli C, Porta MD et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010; 34: 1143-1150.
103. Cermak J, Jonasova A, Vondrakova J et al. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. Hemoglobin 2011; 35: 217-227.
104. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.